‘Rallying to the Challenge’ is a meeting designed for and by people with Parkinson’s, advocates and care partners to explore how the Parkinson’s community can impact and accelerate research.

Each year the meeting takes an aspect of Parkinson’s research and discusses how people living with the condition can support and influence work in this area.

This year the theme for the meeting was ‘GBA1 and LRRK2 – From Genetic Risk to the Clinic’ which mirrored the theme of Van Andel Institute’s ‘Grand Challenges in Parkinson’s Disease’, running alongside.

Due to the pandemic, the Rallying to the Challenge 2021 meeting was held virtually, and the full recordings of each day are available below:

‘Rallying to the Challenge Day One’

From genetic risk to the clinic – or, from peas to pills
Dr Kevin McFarthing
Where can patient involvement really add the punch?
Dr Soania Mathur, PD Avengers
Data collection: concerns and opportunities. Survey findings.
Dr Leah Mursaleen
What are LRRK2 and GBA Parkinson’s?
Dr Laurie Sanders, Duke University
A personal story: carrying LRRK2, my research involvement journey
Jessi Keavney (PD Avenger)
The value of LRRK2 and GBA research: why they are important therapeutic targets.
What is the potential benefit to the broader Parkinson’s community?
Dr Simon Stott, Cure Parkinson’s
The pipeline of genetic clinical trials
Dr Richard Wyse, Cure Parkinson’s

‘Rallying to the Challenge Day Two’

Drug discovery for genetic forms of Parkinson’s:
Marc van Grieken (Dundee Research Interest Group) interviews
Professors Dario Alessi, Miratul Muquit and Dr Esther Sammler
The Need for a Young-onset genetic registry and the efforts to create one
Gaynor Edwards, Spotlight YOPD
Clinical Trials and Research, where does Africa fit in?
Omotola Thomas, Founder Parkinson’s Africa with Rachel Agwu,
Parkinson’s Africa, based in Nigeria with Dr Mie Rizig UCL London
PD Avengers: Larry Gifford highlights the impact to date and activities and where
future support is needed

How helpful was this content?

/ 5. Vote count:

We are sorry that this content was not useful for you

Let us improve this content

Can you tell us how we can improve this content?